AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Celldex Therapeutics Inc. (CLDX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

22.59

-0.46 (-2.00%)

At close: Feb 20, 2025, 3:59 PM

22.00

-2.63%

After-hours: Feb 20, 2025, 05:20 PM EST

undefined% (undefined)

Bid	20.95
Market Cap	1.50B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.58
PE Ratio (ttm)	-8.76
Forward PE	n/a
Analyst	Buy

Ask	23
Volume	244,693
Avg. Volume (20D)	961,338
Open	23.04
Previous Close	23.05
Day's Range	22.55 - 23.11
52-Week Range	20.91 - 53.18
Beta	undefined

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 15, 1986

Employees 160

Stock Exchange NASDAQ

Ticker Symbol CLDX

Website https://www.celldex.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for CLDX stock is "Buy." The 12-month stock price forecast is $67, which is an increase of 196.53% from the latest price.

Buy 62.50%

Hold 37.50%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Celldex Therapeutics Inc. is scheduled to release its earnings on Mar 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

-12.06%

Celldex Therapeutics shares are trading lower. The... Unlock content with Pro Subscription

6 months ago

-8.45%

Celldex Therapeutics shares are trading lower. The company announced topline results from its Phase 2 clinical trial of barzolvolimab.

News

1 month ago · https://thefly.com

Blueprint Medicines price target lowered by $11 at Wedbush, here's why

Blueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%)